openPR Logo
Press release

Head & Neck Cancer Drugs Market on target to reach $2,281 Million, with a CAGR of 7.3% by 2025

03-13-2019 06:51 PM CET | Health & Medicine

Press release from: Allied Market Research

Head & Neck Cancer Drugs Market

Head & Neck Cancer Drugs Market

Latest report pusblished, titled, "Head & Neck Cancer Drugs Market by Drug Class (Chemotherapy, Immunotherapy, and Targeted Therapy) and Sales Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Stores): Global Opportunity Analysis and Industry Forecast, 2018 – 2025."

The report offers an extensive analysis of key market segments, top winning strategies, research methodology, evolving market trends, key segments, list of key players, market size & estimations, and competitive landscape. According to the report, the global head & neck cancer drugs market was estimated at $1.2 billion in 2017 and is expected to hit $2.2 billion in 2025, registering a CAGR of 7.3% from 2018-2025.

Download Sample of the Report @

Recent launch of advance drugs for treatment of head and neck cancer, increase in global geriatric population and rise in consumption of tobacco & alcohol has fueled the growth of global head & neck cancer drugs market. On the other hand, preferable use of radiation therapy over the drug therapy in initial stage has happened to restrain the growth to some extent. Simultaneously, Growth opportunities in emerging market with rise in purchasing power, increase in incidence of head & neck cancer and developing healthcare infrastructure and rise in number of pipeline drugs have made space for multiple opportunities in the sector.

Chemotherapy to maintain its leadership status by 2025

By drug class, chemotherapy contributed to nearly half of the total market and is expected to retain its headship status by 2025. Increase in adoption of chemotherapeutics along with radiation therapy for treatment of head & neck cancer has coaled the growth of the market. Also, rise in use of use of chemotherapeutics drugs in combination with other drugs has fueled the cause in more than one way.

Drug stores & retail pharmacies to rule the market during the estimated period

By sales channel, the drug stores & retail pharmacies segment contributed to nearly three-fifth of the total market and is anticipated to maintain its stand by 2023, airing a CAGR of 6.5%. Easy drug availability in the pharmacies has escalated the growth of the sector.

North America to dominate the market throughout the forecast period

The market of Head & Neck Cancer Drugs is evaluated across various regions including North America, Asia-Pacific, Europe, and Latin America, Middle East and Africa (LAMEA). North America accounted for nearly half of the total market share and is anticipated to maintain a CAGR of 6.3% from 2018-2025. Presence of major key players in the province, easy availability of exclusive drugs, high purchasing power, improved reimbursement policies and increase in prevalence of cancer have made the region hold the largest market share.

For More Info Visit @

Leading market players

Key market players evaluated in the research include Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Merck KGaA (EMD Serono, Inc.), AstraZeneca PLC, Immutep Limited, Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), Merck & Co., Inc., Novartis AG, and Pfizer Inc. The winning strategies they follow have helped them maintain their status in the market. Also, their unique outlook towards the market has been right behind their success story.

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP,
provides business insights and market research reports to large as well as small &
medium enterprises. The company assists its clients to strategize business policies and
achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection
to investment advice. The analysts at Allied Market Research dig out factors that help
clients to understand the significance and impact of market dynamics. The company
amplies client’s insight on the factors, such as strategies, future estimations, growth
or fall forecasting, opportunity analysis, and consumer surveys among others. As
follows, the company offers consistent business intelligent support to aid the clients
to turn into prominent business firm.


David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Head & Neck Cancer Drugs Market on target to reach $2,281 Million, with a CAGR of 7.3% by 2025 here

News-ID: 1652417 • Views: 260

More Releases from Allied Market Research

Smart Inhalers Market is Like to Touch $1,406 Million by 2026
Smart Inhalers Market size was valued to be at $34 million in 2018 and is expected to increase during the forecast period to be at $1,406 million by 2026, registering a CAGR of 58.4% from 2019 to 2026. The inhalers segment accounted for more than half of the total market share in 2018. Smart inhalers are the small inhaler devices used for delivering several inhaled medications such as anticholinergics, glucocorticoids, and
Surgical Sutures Market On Position to Reach $5,255 Million by 2022
Surgical Sutures Market size accounted for $3,360 million in 2015, and is expected to reach $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 to 2022. The sutures segment dominated the market in 2015 with more than four-fifths share. Click Here To Access Free Sample Report: Global escalation in the number of hospitals, surge in the adoption of technologically advanced products, and increase in number of surgeries due
Internet of Things in Healthcare Market Like to Cross $332 Billion by 2027
The global internet of things in healthcare market was valued at $113.751 billion in 2019 and is expected to reach $332.672 billion by 2027, registering a CAGR of 13.20% from 2020 to 2027. The internet of things (IoT) is described as a network of physical devices that uses connectivity to enable the exchange of data. The internet of things in healthcare market is gaining popularity in the recent years owing
Breast Imaging Technologies Market Is Expected to Reach $4,502 Million by 2022
Breast Imaging Technologies Market Report, published by Allied Market Research, forecasts that the global breast imaging technologies market is expected to garner $4,502 million by 2022, registering a CAGR of 8.4% during the period 2016-2022.North America and Europe together accounted for over three-fourths market share in 2015. Ionizing breast imaging technology is expected to maintain its lead throughout the forecast period. The market is expected to be driven by the rise

All 5 Releases

More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample - Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning